Guilford preclinical data

GLFD said its inhibitors of NAALADase, which modulates the release of glutamate, reversed disease progression and provided symptomatic relief of peripheral neuropathy in mice. The compounds also were effective in relieving neuropathic pain at lower doses and with a faster onset of action compared to Pfizer Inc.'s Neurontin gabapentin. In addition, the compounds increased survival and delayed symptom onset in a mouse model of amyotrophic lateral sclerosis (ALS) and prevented loss of retinal ganglion cells in a rat model of glaucoma. Data were presented at the Society for Neuroscience meeting in New Orleans. ...